PAVM

+ Watchlist + Portfolio

PAVmed Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $5.10
52-Week Range: $3.85 – $28.44
Market Cap: $41.42M
P/E (TTM): —
EPS (TTM): -17.21
Dividend Yield: —

Advanced Metrics

Price/Book: 0.91
PEG Ratio: —
Return on Equity: -64.78%
Return on Assets: -39.69%
Gross Margin: -220.54%
Operating Margin: -21278.79%
Profit Margin: 0.00%
Current Ratio: 1.19
Debt/Equity: 0.88
Total Debt: $17.07M
Free Cash Flow: $-11.93M
Revenue Growth: 450.00%
Earnings Growth: —
Enterprise Value: $37.33M

PAVM Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$377.00K	$2.45M	$3.00M	$71.00K
Cost of Revenue	$3.61M	$6.42M	$4.84M	$218.00K
Gross Profit	-$3.24M	-$3.97M	-$1.84M	-$147.00K
Research & Development	$25.34M	$14.28M	$5.93M	$4.49M
Selling, General & Admin	$60.73M	$48.53M	$36.15M	$17.17M
Operating Expenses	$87.85M	$64.83M	$42.53M	$21.24M
Operating Income	-$91.09M	-$68.80M	-$44.38M	-$21.39M
EBITDA	-$99.50M	-$75.74M	$29.67M	-$2.34M
Pretax Income	-$103.24M	-$79.26M	$28.43M	-$2.47M
Income Tax	$0.00	$0.00	$0.00	$0.00
Net Income	-$88.98M	-$64.17M	$39.79M	$401.00K
Diluted EPS	-450.90	-274.80	15.00	1.84
Diluted Shares	197946	241051	373299	927933

PAVM Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$39.74M	$19.64M	$1.19M	$1.54M
Receivables	$17.00K	$61.00K	$18.00K	$15.00K
Inventory	$261.00K	$539.00K	$266.00K	$239.00K
Current Assets	$43.93M	$24.50M	$2.16M	$2.56M
Total Assets	$53.98M	$33.12M	$30.66M	$38.81M
Current Liabilities	$41.20M	$54.18M	$35.45M	$14.84M
Total Debt	$36.64M	$48.73M	$31.86M	$13.35M
Total Liabilities	$43.05M	$57.14M	$37.69M	$16.51M
Retained Earnings	-$228.17M	-$294.43M	-$254.97M	-$258.73M
Shareholders' Equity	-$9.68M	-$53.83M	-$2.50M	$33.97M
Working Capital	$2.73M	-$29.68M	-$33.28M	-$12.28M
Net Debt	—	$24.56M	$27.91M	$9.56M

PAVM Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$70.98M	-$52.04M	-$33.55M	-$5.21M
Capital Expenditure	-$1.54M	-$242.00K	-$55.00K	-$31.00K
Free Cash Flow	-$72.53M	-$52.28M	-$33.61M	-$5.24M
Depreciation & Amortisation	$2.46M	$2.93M	$1.20M	$105.00K
Stock-Based Compensation	$19.53M	$11.14M	$6.45M	$1.71M
Investing Cash Flow	-$4.74M	$758.00K	-$16.18M	-$31.00K
Financing Cash Flow	$38.21M	$31.17M	$31.28M	$5.59M
Share Repurchases	-$366.00K	$0.00	—	—
Net Change in Cash	-$37.51M	-$20.11M	-$18.45M	$353.00K

PAVM Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$8.00K	$6.00K	$5.00K	$52.00K	$22.00K
Cost of Revenue	$36.00K	$41.00K	$55.00K	$85.00K	$97.00K
Gross Profit	-$28.00K	-$35.00K	-$50.00K	-$33.00K	-$75.00K
Research & Development	$787.00K	$790.00K	$1.09M	$1.83M	$1.39M
Selling, General & Admin	$4.63M	$3.89M	$3.71M	$4.94M	$6.57M
Operating Expenses	$5.40M	$4.60M	$4.63M	$6.62M	$7.79M
Operating Income	-$5.43M	-$4.63M	-$4.68M	-$6.65M	-$7.87M
EBITDA	$18.67M	-$12.30M	-$5.98M	-$2.73M	-$1.04M
Pretax Income	$18.62M	-$12.32M	-$6.01M	-$2.76M	-$1.06M
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	$18.97M	-$11.92M	-$5.38M	-$1.26M	-$60.00K
Diluted EPS	10.10	-22.20	-8.70	-61.50	-4.42
Diluted Shares	1.75M	602821	718484	927933	1.58M

PAVM Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$2.70M	$4.00M	$3.10M	$1.54M	$6.46M
Receivables	$9.00K	$3.00K	$3.00K	$15.00K	$21.00K
Inventory	$263.00K	$260.00K	$245.00K	$239.00K	$236.00K
Current Assets	$3.64M	$5.49M	$4.19M	$2.56M	$7.41M
Total Assets	$52.82M	$43.89M	$38.07M	$38.81M	$45.42M
Current Liabilities	$9.78M	$10.51M	$10.46M	$14.84M	$3.66M
Long-Term Debt	—	—	—	—	$14.90M
Total Debt	$9.24M	$9.31M	$9.28M	$13.35M	$17.01M
Total Liabilities	$11.89M	$12.47M	$12.28M	$16.51M	$20.43M
Retained Earnings	-$237.27M	-$250.57M	-$256.90M	-$258.73M	-$259.03M
Shareholders' Equity	$46.99M	$40.79M	$35.78M	$33.97M	$39.52M
Working Capital	-$6.14M	-$5.02M	-$6.27M	-$12.28M	$3.75M
Net Debt	$3.90M	$2.80M	$3.80M	$9.56M	$8.44M

PAVM Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$1.58M	-$1.18M	-$896.00K	-$1.55M	-$2.62M
Capital Expenditure	-$6.00K	-$8.00K	-$3.00K	-$14.00K	-$22.00K
Free Cash Flow	-$1.59M	-$1.19M	-$899.00K	-$1.56M	-$2.64M
Depreciation & Amortisation	$43.00K	$22.00K	$22.00K	$18.00K	$20.00K
Stock-Based Compensation	$930.00K	$162.00K	$383.00K	$232.00K	$182.00K
Investing Cash Flow	-$6.00K	-$8.00K	-$3.00K	-$14.00K	-$22.00K
Financing Cash Flow	$3.10M	$2.49M	-$2.00K	$0.00	$7.56M
Share Repurchases	$0.00	—	—	—	-$26.20M
Net Change in Cash	$1.51M	$1.30M	-$901.00K	-$1.56M	$4.92M

Market Snapshot

About

PAVmed is a diversified medical device company developing and commercializing innovative products across multiple therapeutic areas. The company focuses on minimally invasive technologies and diagnostic tools designed to improve patient outcomes and reduce healthcare costs, with products spanning gastroenterology, cardiology, and oncology applications.